Dr. Zhenwei Miao

Chairman & CEO

Ph.D. in Chemistry from Peking University; Postdoctoral researcher at Vanderbilt University, USA; Expert of Zhejiang Province's "Thousand Talents Program"; Leading Talent of Hangzhou 5050 Plan (Category A) and 521 Talent.

Former Chief Scientist at Enanta (NASDAQ listed) and Director of Chemistry at Ambrx (NASDAQ listed).

One of the principal inventors of the novel anti-hepatitis C drug Viekira Pak.

Global leader in ADC and renowned expert in Antibody-Cell Conjugate (ACC) NK cells.